Literature DB >> 18268501

Case-control studies show that a non-conservative amino-acid change from a glutamine to arginine in the P2RX7 purinergic receptor protein is associated with both bipolar- and unipolar-affective disorders.

A McQuillin1, N J Bass, K Choudhury, V Puri, M Kosmin, J Lawrence, D Curtis, H M D Gurling.   

Abstract

Three linkage studies of bipolar disorder have implicated chromosome 12q24.3 with lod scores of over 3.0 and several other linkage studies have found lods between 2 and 3. Fine mapping within the original chromosomal linkage regions has identified several loci that show association with bipolar disorder. One of these is the P2RX7 gene encoding a central nervous system-expressed purinergic receptor. A non-synonymous single nucleotide polymorphism, rs2230912 (P2RX7-E13A, G allele) and a microsatellite marker NBG6 were both previously found to be associated with bipolar disorder (P=0.00071 and 0.008, respectively). rs2230912 has also been found to show association with unipolar depression. The effect of the polymorphism is non-conservative and results in a glutamine to arginine change (Gln460Arg), which is likely to affect P2RX7 dimerization and protein-protein interactions. We have confirmed the allelic associations between bipolar disorder and the markers rs2230912 (P2RX7-E13A, G allele, P=0.043) and NBG6 (P=0.010) in a London-based sample of 604 bipolar cases and 560 controls. When we combined these data with the published case-control studies of P2RX7 and mood disorder (3586 individuals) the association between rs2230912 (Gln460Arg) and affective disorders became more robust (P=0.002). The increase in Gln460Arg was confined to heterozygotes rather than homozygotes suggesting a dominant effect (odds ratio 1.302, CI=1.129-1.503). Although further research is needed to prove that the Gln460Arg change has an aetiological role, it is so far the most convincing mutation to have been found with a role for increasing susceptibility to bipolar and genetically related unipolar disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18268501     DOI: 10.1038/mp.2008.6

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  41 in total

1.  Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567.

Authors:  Anindya Bhattacharya; Qi Wang; Hong Ao; James R Shoblock; Brian Lord; Leah Aluisio; Ian Fraser; Diane Nepomuceno; Robert A Neff; Natalie Welty; Timothy W Lovenberg; Pascal Bonaventure; Alan D Wickenden; Michael A Letavic
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

Review 2.  Integrating neuroimmune systems in the neurobiology of depression.

Authors:  Eric S Wohleb; Tina Franklin; Masaaki Iwata; Ronald S Duman
Journal:  Nat Rev Neurosci       Date:  2016-06-09       Impact factor: 34.870

3.  Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode.

Authors:  Giacomo Salvadore; Carlos I Viale; David A Luckenbaugh; Vanessa C Zanatto; Luiz V Portela; Diogo O Souza; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-03-03       Impact factor: 5.067

4.  Genome-wide searches for bipolar disorder genes.

Authors:  Shaza Alsabban; Margarita Rivera; Peter McGuffin
Journal:  Curr Psychiatry Rep       Date:  2011-12       Impact factor: 5.285

5.  Case-case genome-wide association analysis shows markers differentially associated with schizophrenia and bipolar disorder and implicates calcium channel genes.

Authors:  David Curtis; Anna E Vine; Andrew McQuillin; Nicholas James Bass; Ana Pereira; Radhika Kandaswamy; Jacob Lawrence; Adebayo Anjorin; Khalid Choudhury; Susmita R Datta; Vinay Puri; Robert Krasucki; Jonathan Pimm; Srinivasa Thirumalai; Digby Quested; Hugh M D Gurling
Journal:  Psychiatr Genet       Date:  2011-02       Impact factor: 2.458

Review 6.  Purinergic system in psychiatric diseases.

Authors:  A Cheffer; A R G Castillo; J Corrêa-Velloso; M C B Gonçalves; Y Naaldijk; I C Nascimento; G Burnstock; H Ulrich
Journal:  Mol Psychiatry       Date:  2017-09-26       Impact factor: 15.992

7.  CaMKIIα expression in a mouse model of NMDAR hypofunction schizophrenia: Putative roles for IGF-1R and TLR4.

Authors:  O M Ogundele; C C Lee
Journal:  Brain Res Bull       Date:  2017-11-11       Impact factor: 4.077

8.  Candidate region linkage analysis in twins discordant or concordant for depression symptomatology.

Authors:  L Christiansen; Q Tan; T A Kruse; M McGue; K Christensen
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-06-05       Impact factor: 3.568

9.  Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment.

Authors:  Sonja Horstmann; Susanne Lucae; Andreas Menke; Johannes M Hennings; Marcus Ising; Darina Roeske; Bertram Müller-Myhsok; Florian Holsboer; Elisabeth B Binder
Journal:  Neuropsychopharmacology       Date:  2009-11-18       Impact factor: 7.853

10.  Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine.

Authors:  Inge Sillaber; Markus Panhuysen; Markus S H Henniger; Frauke Ohl; Claudia Kühne; Benno Pütz; Thomas Pohl; Jan M Deussing; Marcelo Paez-Pereda; Florian Holsboer
Journal:  Psychopharmacology (Berl)       Date:  2008-07-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.